Patents by Inventor Abraham Bout
Abraham Bout has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 7932360Abstract: The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: GrantFiled: November 6, 2006Date of Patent: April 26, 2011Assignee: Merus B.V.Inventors: Patrick H. C. Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
-
Patent number: 7927834Abstract: The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: GrantFiled: July 29, 2008Date of Patent: April 19, 2011Assignee: Merus B.V.Inventors: Patrick H. C. Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
-
Patent number: 7906113Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: GrantFiled: October 25, 2006Date of Patent: March 15, 2011Assignee: Crucell Holland B.V.Inventors: Abraham Bout, Menzo Havenga, Ronald Vogels
-
Patent number: 7820440Abstract: The invention relates to methods and means for producing adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products provided by the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: May 7, 2007Date of Patent: October 26, 2010Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Abraham Bout
-
Patent number: 7785833Abstract: Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in which the proteinaceous molecule is expressed. Preferably, the predetermined post-translational modifications include glycosylation. Also described are methods for obtaining and producing proteinaceous molecules, using mammalian cells obtainable by a method of the present invention. Preferably, the proteinaceous molecules include erythropoietin (EPO), since EPO's effect depends heavily on its glycosylation pattern. Mammalian cells that have been obtained on the basis of their ability to produce proteins and/or post-translational modifications that are indicative for a predetermined post-translational modification that is desired are also provided.Type: GrantFiled: January 24, 2007Date of Patent: August 31, 2010Assignee: Crucell Holland B.V.Inventors: Dirk Jan Elbertus Opstelten, Johan Christiaan Kapteyn, Petrus Christianius Johannes Josephus Passier, Ronald Hendrik Peter Brus, Abraham Bout
-
Patent number: 7749493Abstract: The present invention provides methods and vector systems for the generation of chimeric recombinant adenoviruses. These hybrid adenoviruses contain a genome that is derived from different adenovirus serotypes. In particular, novel hybrid adenoviruses are disclosed with improved properties for gene therapy purposes. These properties include: a decreased sensitivity towards neutralizing antibodies, a modified host range, a change in the titer to which adenovirus can be grown, the ability to escape trapping in the liver upon in vivo systemic delivery, and absence or decreased infection of antigen presenting cells (APC) of the immune system, such as macrophages or dendritic cells. These chimeric adenoviruses thus represent improved tools for gene therapy and vaccination since they overcome the limitations observed with the currently used serotype subgroup C adenoviruses.Type: GrantFiled: August 18, 2005Date of Patent: July 6, 2010Assignee: Crucell Holland B.V.Inventors: Menzo Havenga, Ronald Vogels, Abraham Bout
-
Patent number: 7696157Abstract: Described are methods for identifying, selecting, and obtaining mammalian cells capable of producing proteinaceous molecules having predetermined post-translational modifications, wherein the post-translational modifications are brought about by the mammalian cell in which the proteinaceous molecule is expressed. Preferably, the predetermined post-translational modifications include glycosylation. Also described are methods for obtaining and producing proteinaceous molecules, using mammalian cells obtainable by a method of the present invention. Preferably, the proteinaceous molecules include erythropoietin (EPO), since EPO's effect depends heavily on its glycosylation pattern. Mammalian cells that have been obtained on the basis of their ability to produce proteins and/or post-translational modifications that are indicative for a predetermined post-translational modification that is desired are also provided.Type: GrantFiled: August 1, 2007Date of Patent: April 13, 2010Assignee: Crucell Holland B.V.Inventors: Dirk Jan Elbertus Opstelten, Johan Christiaan Kapteyn, Petrus Christianus Johannes Josephus Passier, Ronald Hendrik Peter Brus, Abraham Bout
-
Publication number: 20090263864Abstract: The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: ApplicationFiled: July 29, 2008Publication date: October 22, 2009Inventors: Patrick H. C. Van Berkel, Ronald Hendrik Peter Brus, Ton Logtenberg, Abraham Bout
-
Publication number: 20090253207Abstract: A gene delivery vehicle having been provided with at least a tissue tropism for cells selected from the group of smooth muscle cells, endothelial cells, and/or liver cells. The tissue tropism is generally provided by a virus capsid, such as one comprising protein fragments from at least two different viruses, such as two different adenoviruses, including adenovirus of subgroup C or subgroup B (for example, adenovirus 16). The protein fragments can comprise a tissue tropism-determining fragment of a fiber protein derived from a subgroup B adenovirus. Also, cells for producing such gene delivery vehicles and pharmaceutical compositions containing these gene delivery vehicles are provided.Type: ApplicationFiled: May 28, 2009Publication date: October 8, 2009Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Menzo J. E. Havenga, Abraham Bout
-
Publication number: 20090170164Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: ApplicationFiled: November 14, 2008Publication date: July 2, 2009Applicant: Crucell Holland B.V.Inventors: Abraham Bout, Guus Hatebaer, Karina Cornelia Verhulst, Alphonsus Gerarous Llytdehaas, Govert Johan Schonte
-
Patent number: 7537916Abstract: The present invention provides immortalized eukaryotic cells and methods useful for the production of immunologically active bivalent antibody fragments, such as F(ab?)2 fragments. The methods and cells of the invention result in a desirable ratio of bivalent to monovalent antibody fragments.Type: GrantFiled: February 14, 2008Date of Patent: May 26, 2009Assignee: Crucell Holland B.V.Inventors: David Halford Ashton Jones, Abraham Bout
-
Patent number: 7491532Abstract: Methods and compositions for the production of recombinant proteins in a eukaryotic cell line are disclosed. The methods and compositions are particularly useful for generating stable expression of recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: GrantFiled: March 1, 2004Date of Patent: February 17, 2009Assignee: Crucell Holland, B.V.Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Publication number: 20090023196Abstract: Presented are ways to address the problem of replication-competent adenovirus in adenoviral production for use with, for example, gene therapy. Packaging cells having no overlapping sequences with a selected vector are suited for large scale production of recombinant adenoviruses. A system for use with the invention produces replication-defective adenovirus. The system includes a primary cell containing a nucleic acid based on or derived from adenovirus and an isolated recombinant nucleic acid molecule for transfer into the primary cell. The isolated recombinant nucleic acid molecule is based on or derived from an adenovirus, has at least one functional encapsidation signal and at least one functional Inverted Terminal Repeat, and lacks overlapping sequences with the nucleic acid of the cell. Otherwise, the overlapping sequences would enable homologous recombination leading to replication-competent adenovirus in the primary cell into which the isolated recombinant nucleic acid molecule is to be transferred.Type: ApplicationFiled: July 16, 2007Publication date: January 22, 2009Inventors: Frits J. Fallaux, Robert C. Hoeben, Alex Jan van der Eb, Abraham Bout, Domenico Valerio
-
Patent number: 7470523Abstract: Methods and compositions for the production of recombinant proteins in a human cell line. The methods and compositions are particularly useful for generating stable expression of human recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: GrantFiled: November 3, 2006Date of Patent: December 30, 2008Assignee: Crucell Holland B.V.Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert John Schouten
-
Patent number: 7468181Abstract: The invention relates to methods and means for the production of adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products provided by the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: GrantFiled: April 24, 2003Date of Patent: December 23, 2008Assignee: Crucell Holland B.V.Inventors: Ronald Vogels, Abraham Bout
-
Publication number: 20080274497Abstract: Methods and compositions for the production of recombinant proteins in a eukaryotic cell line are disclosed. The methods and compositions are particularly useful for generating stable expression of recombinant proteins of interest that are modified post-translationally, for example, by glycosylation. Such proteins may have advantageous properties in comparison with their counterparts produced in non-human systems such as Chinese hamster ovary cells.Type: ApplicationFiled: March 1, 2004Publication date: November 6, 2008Inventors: Abraham Bout, Guus Hateboer, Karina Cornelia Verhulst, Alphonsus Gerardus Uytdehaag, Govert Johan Schouten
-
Patent number: 7429486Abstract: The invention provides methods for producing mixtures of antibodies from a single host cell clone, wherein, a nucleic acid sequence encoding a light chain and nucleic acid sequences encoding different heavy chains are expressed in a recombinant host cell. The recombinantly produced antibodies in the mixtures according to the invention suitably comprise identical light chains paired to different heavy chains capable of pairing to the light chain, thereby forming functional antigen-binding domains. Mixtures of the recombinantly produced antibodies are also provided by the invention. Such mixtures can be used in a variety of fields.Type: GrantFiled: November 6, 2006Date of Patent: September 30, 2008Assignee: Crucell Holland B.V.Inventors: Patrick H. C. Van Berkel, Ronald H. P. Brus, Ton Logtenberg, Abraham Bout
-
Publication number: 20080199917Abstract: The invention relates to methods and means for producing adenoviral vectors on complementing cell lines, wherein the early region 4 open reading frame 6 (E4-orf6) encoding nucleic acid is present in the adenoviral vector and wherein the E4-orf6 gene product is compatible with one or more products of the E1 gene products provided by the complementing cell, such that the adenoviral vector can be efficiently produced by the complementing cell.Type: ApplicationFiled: May 7, 2007Publication date: August 21, 2008Applicant: Crucell Holland B.V.Inventors: Ronald Vogels, Abraham Bout
-
Publication number: 20080171018Abstract: Adenovirus serotypes differ in their natural tropism. The adenovirus serotypes 2, 4, 5 and 7 all have a natural affiliation towards lung epithelia and other respiratory tissues. In contrast, serotypes 40 and 41 have a natural affiliation towards the gastrointestinal tract. The serotypes described, differ in at least capsid proteins (penton-base, hexon), proteins responsible for cell binding (fiber protein), and proteins involved in adenovirus replication. This difference in tropism and capsid protein among serotypes has led to the many research efforts aimed at redirecting the adenovirus tropism by modification of the capsid proteins.Type: ApplicationFiled: October 29, 2007Publication date: July 17, 2008Applicant: Crucell Holland B.V.Inventors: Abraham Bout, Menzo Havenga, Ronald Vogels
-
Publication number: 20080166767Abstract: The present invention provides immortalized eukaryotic cells and methods useful for the production of immunologically active bivalent antibody fragments, such as F(ab?)2 fragments. The methods and cells of the invention result in a desirable ratio of bivalent to monovalent antibody fragments.Type: ApplicationFiled: February 14, 2008Publication date: July 10, 2008Applicant: Crucell Holland B.V.Inventors: David Halford Ashton Jones, Abraham Bout